<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160805</url>
  </required_header>
  <id_info>
    <org_study_id>ONL1204-OAG-001</org_study_id>
    <nct_id>NCT05160805</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients With Progressing Open Angle Glaucoma</brief_title>
  <official_title>A Phase 1b Multicenter, Randomized, Single-Masked, Sham-Controlled Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients With Progressing Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ONL Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ONL Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and tolerability of ONL1204 Ophthalmic&#xD;
      Solution in patients with progressing open angle glaucoma.&#xD;
&#xD;
      ONL1204 Ophthalmic Solution is a first-in-class inhibitor of fragment apoptosis stimulator&#xD;
      (Fas) receptor-mediated cell death that has demonstrated protection of multiple retinal cell&#xD;
      types in numerous preclinical models of retinal disease. Apoptosis of retinal ganglion cells&#xD;
      is associated with progressive glaucoma. Nonclinical data on ONL1204 Ophthalmic Solution&#xD;
      suggest that ONL1204 Ophthalmic Solution may inhibit the cell death pathways in these cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of ONL1204 as assessed by AE reporting and clinical evaluations</measure>
    <time_frame>up to 39 weeks</time_frame>
    <description>Adverse event reporting, ophthalmic examination to evaluate the anterior and posterior segments of the eye, best-corrected visual acuity, intraocular pressure, electroretinogram, vital signs, clinical laboratory evaluations, and ophthalmic imaging results</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONL1204 Ophthalmic solution (Dose A) administered by intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONL1204 Ophthalmic solution (Dose B) administered by intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group C</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham procedure without penetrating the eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONL1204 Ophthalmic solution (Dose A)</intervention_name>
    <description>Liquid formulation administered by intravitreal (IVT) injection</description>
    <arm_group_label>Treatment Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONL1204 Ophthalmic solution (Dose B)</intervention_name>
    <description>Liquid formulation administered by intravitreal (IVT) injection</description>
    <arm_group_label>Treatment Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.</description>
    <arm_group_label>Treatment Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females aged ≥18 years old&#xD;
&#xD;
          2. Able and willing to give informed consent and attend study visits&#xD;
&#xD;
          3. Controlled intraocular pressure (IOP) (≤21 mmHg) in both eyes&#xD;
&#xD;
          4. Prior to screening, 3 or more Humphrey Visual Field (HVF) tests (with acceptable&#xD;
             reliability standards) or 3 or more Optical Coherence Tomography (OCT) studies of the&#xD;
             study eye on record&#xD;
&#xD;
          5. Open angle glaucoma that is progressing in the study eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Considerations for either eye&#xD;
&#xD;
          1. Best Corrected Visual Acuity (BCVA) at Baseline of ≤64 letters (Snellen equivalent of&#xD;
             worse than 20/50)&#xD;
&#xD;
          2. Severe open angle glaucoma&#xD;
&#xD;
          3. Glaucoma due to non-open angle causes&#xD;
&#xD;
          4. Worse than mild non-proliferative diabetic retinopathy&#xD;
&#xD;
             Considerations for study eye:&#xD;
&#xD;
          5. Visual field results suggestive of another disease (eg, altitudinal field defect)&#xD;
&#xD;
          6. Evidence of macular edema based on OCT imaging and Investigator's judgement&#xD;
&#xD;
          7. Previous intravitreal (IVT) injections, history of retinal surgery, history of retinal&#xD;
             laser&#xD;
&#xD;
          8. Cataract surgery within 3 months of Screening or yttrium-aluminum-garnet capsulotomy&#xD;
             (YAG) within 4 weeks of Screening&#xD;
&#xD;
          9. Anticipated need for surgical or procedural intervention for glaucoma, cataract,&#xD;
             posterior capsular opacity, refractive error, or retinal conditions during the study&#xD;
&#xD;
             Other general exclusion criteria:&#xD;
&#xD;
         10. The requirement for oral carbonic anhydrase inhibitors to control intraocular pressure&#xD;
&#xD;
         11. Severe, unstable, or uncontrolled cardiovascular, diabetic, renal, or pulmonary&#xD;
             disease, based on Investigator's judgement&#xD;
&#xD;
         12. Systolic blood pressure &gt;180 mmHg or diastolic blood pressure &gt;110 mmHg&#xD;
&#xD;
         13. Women who are pregnant, breastfeeding, or contemplating pregnancy during the study&#xD;
             period and men who are contemplating contributing sperm for a biologic child during&#xD;
             the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chief Operating Officer</last_name>
    <phone>734-412-8787</phone>
    <email>info@onltherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albury Eye Clinic Wodonga</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Alex Breen</last_name>
      <email>AECResearch@alburyeye.com.au</email>
    </contact>
    <investigator>
      <last_name>Paul Giles, MBBS (Hons)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Eye Research Australia (CERA)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Thuy Chau</last_name>
      <email>thuy.chau@unimelb.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Marios Constaninou</last_name>
      <email>mariosc@unimelb.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Keith Martin, BM BCh DM MRCP FRCOphth ALCM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.onltherapeutics.com/clinical-trials/</url>
    <description>ONL Therapeutics corporate website</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 6, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progressing</keyword>
  <keyword>Glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

